.png "Amicus (NASDAQ: FOLD)")
In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Amicus (NASDAQ: FOLD), with a price target of $22. The company’s shares opened today at $13.66.
According to TipRanks.com, Baral is a top 25 analyst with an average return of 34.3% and a 55.9% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.
Amicus has an analyst consensus of Moderate Buy, with a price target consensus of $19.
Find more picks by Best Performing Analysts >>
Based on Amicus’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $69.21 million. In comparison, last year the company had a GAAP net loss of $54.99 million.
Based on the recent corporate insider activity of 62 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of FOLD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amicus Therapeutics, Inc. is a biotechnology company, which is engaged in the discovery, development and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease.
